SUNNYVALE, CA and SLOUGH, UNITED KINGDOM --
PLEASANTON, CA --
Fuel (NASDAQ:FUEL), a leading provider of artificial intelligence
(AI) advertising and marketing solutions for global agencies and brands,
today announced that this fall it will release a new feature of its
Mission Control platform that will provide its managed-service customers
with real-time access to campaign reporting and analytics.
(NASDAQ: QLIK), a leader in data discovery, today announced that Fujitsu
Limited has integrated QlikView® into its Big Data solution, the Fujitsu
Business Application Operational Data Management & Analytics (ODMA)
solution, to provide improved data visualization and analysis for
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders,
including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today
announced that it will hold an Analyst and Investor Event in New York
City, New York on Thursday, October 9, 2014.
Sign-up for OCWEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ocwen Financial Corp. -- OCN investment picks
Sign-up for ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd. investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food
and Drug Administration (FDA) has approved Harvoni ®
(ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet
regimen for the treatment of chronic hepatitis C genotype 1 infection in
Sign-up for U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.